Helen of Troy
This article was originally published in The Rose Sheet
Executive Summary
Fiscal 2004 third quarter net sales advanced 25.3% to $179.2 mil. with growth in all business segments except Tactica, Helen of Troy reports Jan. 14. Idelle Labs, which includes the Sea Breeze, Final Net, 3-in-1 brands acquired from P&G in 2002, as well as Brut cologne purchased from Unilever in September, accounted for roughly 30% of growth, or $12.3 mil., in Q3 (ended Nov. 30). Revenues for the Tactica depilatory business fell about 27% during the period to $13.8 mil. due to softness in the infomercial channel and a decline in Epil Stop sales. Helen of Troy recently announced it is "evaluating strategic alternatives" for Tactica (1"The Rose Sheet" Oct. 6, 2003, p. 7). Net income during the period rose 49.3% to $25.1 mil. The company also raised its fiscal year earnings per diluted share guidance from $1.85-$1.90 to $2.05-$2.10...
You may also be interested in...
Helen Of Troy Exploring Options For Tactica Depilatory Business
Helen of Troy is "evaluating strategic alternatives" for its investment in Tactica, the firm's depilatory products business, Chairman, President and CEO Gerald Rubin announced during a second quarter sales and earnings presentation Oct. 2
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.